Total Funding
33
76
Total FundingVenture - Series Unknown raised
Growth Score
-2 pts
Heat Score
-4 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
129319
Proterris, a P2 clinical-stage firm, has pooled a dominant IP position in therapeutic uses of inhaled and small-molecule carbon monoxide.
Jeffrey D. Wager: CEO, Chairman and Co-FounderPast Role: Artisan Pharma, Co-founder, President & CEO- Joseph Wager: Founder and CEO
About the Company
Proterris, a P2 clinical-stage firm, has pooled a dominant IP position in therapeutic uses of inhaled and small-molecule carbon monoxide. Proterris has prioritized CO development in delayed graft function (DGF), acute liver failure, and non-alcoholic steatohepatitis (NASH), with significant opportunities in a number of other indications, including
but not limited to acute kidney injury (AKI), renal fibrosis, and idiopathic pulmonary fibrosis (IPF).
It is headquartered in Boston, Massachusetts.
